Aduro Biotech — Investor Presentation (January 2016)
39 slides from Aduro Biotech's investor presentation, Jan 11, 2016
Slide 1: Company Overview January 2016
Company Overview January 2016 Exhibit 99.1
Slide 2: Disclaimer: Special Note Regarding Forward-Looking Statements
Disclaimer Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. (“Aduro”) that are not historical fa
Slide 3: Aduro Highlights
Aduro Highlights Three diverse and versatile immunotherapy platforms LADD – novel, live-attenuated Listeria platform to deliver tumor antigens Survival benefit demonstrated in randomized Phase 2 trial in pancreatic cancer trial 94% disease control rate in Phase 1b mesothelioma trial Two Phase 1 tria
Slide 4: 2015 Accomplishments
2015 Accomplishments Corporate achievements Raised ~$175 million in Series D and IPO Signed $750M CDN collaboration with Novartis targeting STING pathway in oncology Acquired BioNovion, a monoclonal antibody company; launched Aduro Biotech Europe Clinical achievements Published Phase 2a pancreatic c
Slide 5: Aduro's Place in Cancer Therapy
Aduro’s Place in Cancer Therapy Physicians and scientists are changing the way they think about the biology and treatment of cancer Emerging paradigm: Combinations of conventional and novel immuno-oncology therapies aimed to improve cancer patient survival Aduro has the potential to assume an import
Slide 6: Enhancing Therapeutic Strength through Combinations
Enhancing Therapeutic Strength through Combinations Chemo- therapy Immune Agonists Radio- therapy Checkpoint Inhibitors Targeted Therapies GVAX / Cellular Therapies LADD CDN B-select mAbs Breadth of Potential Combinations with Conventional and Novel Therapies ADURO PLATFORMS 6
Slide 7: LADD Platform: Promising Vector to Induce Innate & Adaptive Immunity
LADD Platform: Promising Vector to Induce Innate & Adaptive Immunity Proprietary gene engineering for safety and efficacy Deletion of two virulence genes substantially reduces disease-causing properties Multivalent antigen cassettes for antigen expression Favorable safety profile in trials to date I
Slide 8: LADD Platform Stimulates Innate Immunity Responses and Antigen-specific T Cell Responses
LADD Platform Stimulates Innate Immunity Responses and Antigen-specific T Cell Responses
Slide 9: CDN Platform: Off-the-Shelf Patient Specific Immunity
CDN Platform: Off-the-Shelf Patient Specific Immunity Targets and activates STING – central mediator of innate immunity Proprietary synthetic CDN structures Activate all known human STING receptors Synthetic compounds more potent than natural STING ligands Significant anti-tumor activity in pre-clin
Slide 10: CDNs Activate Innate & Adaptive Immunity through STING
CDNs Activate Innate & Adaptive Immunity through STING
Slide 11: B-select Monoclonal Antibodies
Soluble Ligands B-select Monoclonal Antibodies Targets First- or Best-in-Class Agonist and Antagonist mAbs Confidential Blocking antibodies APRIL
Slide 12: Aduro's Development Pipeline
Program Indication Combination Discovery / Preclinical Phase 1 Phase 2 Phase 3 LADD Programs CRS-207 Pancreatic GVAX Pancreatic GVAX+αPD-1 Mesothelioma Chemo Ovarian Epacadostat ADU-623 Glioblastoma None ADU-741 Prostate TBD ADU-214 Lung Multiple / TBD CDN Programs ADU-S100 Palpable tumors Adjuvant
Slide 13: Clinical Programs CRS-207: LADD Strain Expressing Mesothelin Tumor Antigen
Clinical Programs CRS-207: LADD Strain Expressing Mesothelin Tumor Antigen
Slide 14: CRS-207: Pancreatic Cancer
CRS-207: Pancreatic Cancer Phase 2a: CRS-207 + GVAX (Completed) Demonstrated survival benefit vs. GVAX Pancreas alone Favorable safety profile to date Continue to treat and monitor long-term survivors Phase 2b: CRS-207 + GVAX (Fully Enrolled) Primary endpoint: Overall survival superiority vs. chemot
Slide 15: CRS-207: Pancreatic Cancer Promising Phase 2a Results with Long-Term Survivors
Long-term Tail Time (Months) on Study Survival Probability CRS-207: Pancreatic Cancer Promising Phase 2a Results with Long-Term Survivors 2:1 24 mo. follow-up 24 mo. follow-up R CRS-207 GVAX Pancreas Subjects may continue on additional courses of treatment if clinically stable Median OS 6.1 vs. 3.9
Slide 16: CRS-207: Pancreatic Cancer Comprehensive Phase 2b Trial Fully Enrolled
CRS-207: Pancreatic Cancer Primary endpoint: Overall survival in Arm A vs Arm C (third line) Statistical design: 80% power, hazard ratio=0.67, α=0.15 (one-sided) Secondary endpoints include: Safety, progression-free survival, tumor response rate and quality of life Top line data expected late Q2 201
Slide 17: CRS-207: Pancreatic Cancer Combination with Checkpoint Inhibitors
24 mo. follow-up CRS-207: Pancreatic Cancer Primary endpoint: Overall survival Secondary endpoints: Clinical response and safety Interim data expected to be reported in 2H 2016 Investigator-sponsored study supported by Aduro, Bristol-Myers Squibb, Stand Up to Cancer, PanCAN/AACR and Lustgarten Found
Slide 18: CRS-207: Pancreatic Cancer Phase 3 Planning and Manufacturing
CRS-207: Pancreatic Cancer Trial design concept Global study in metastatic pancreatic cancer patients who received prior chemotherapy Opportunity to evaluate as a second-line therapy Primary endpoint: Overall survival Final design based on ECLIPSE results Finalize plan in 2H 2016 Technology transfer
Slide 19: CRS-207: Mesothelioma
CRS-207: Mesothelioma Phase 1b: Front line combination of CRS-207 and chemotherapy (Fully Enrolled) Single arm trial in combination with SOC chemotherapy Safety and efficacy data updated at ESMO 2015 59% partial response rate, 94% disease control rate in front line patients Sites remain open for con
Slide 20: CRS-207: Mesothelioma Phase 1b Clinical Trial
CRS-207: Mesothelioma Primary endpoints: Safety and immune response Secondary endpoints: Tumor response, time to progression, progression-free survival, overall survival, immune analyses, tumor marker kinetics Survival results expected in 1H 2016 Phase 1b Clinical Trial in Mesothelioma Patients may
Slide 21: CRS-207: Mesothelioma Best Overall Response of Target Lesions
CRS-207: Mesothelioma Best Overall Response of Target Lesions 85% of subjects experienced tumor shrinkage ESMO 2015
Slide 22: CRS-207 + Epacadostat: Ovarian Cancer
CRS-207 + Epacadostat: Ovarian Cancer Planned Phase 1/2 Trial Design 1:1 R Platinum‑resistant Ovarian, Fallopian, or Peritoneal Cancer Patients Part 1 (Up to 42 patients) Safety & Biomarker Evaluation Part 2 (Up to 86 patients) Primary Objective: Dose Selection Primary Objective: ORR and PFS Patient
Slide 23: Cyclic Dinucleotides (CDN) Small Molecules Targeting STING
Cyclic Dinucleotides (CDN) Small Molecules Targeting STING (Stimulator of Interferon Genes)
Slide 24: First-in-Human Clinical Study to Target STING
First-in-Human Clinical Study to Target STING ADU-S100 Clinical Trial in H1 2016 ADU-S100 induces innate immunity through STING STING is the critical receptor to activate immune cells including dendritic cells in the tumor microenvironment IT injection of ADU-S100 leads to an “inflamed” tumor phenot
Slide 25: CDN: Encouraging Preclinical Data
CDN: Encouraging Preclinical Data Activity in B16 Melanoma Tumor Model Significantly Better than TLR Ligands Groups: (N=8) Proprietary CDN versus TLR Ligands Proprietary CDN versus Naturally Occurring Injections P<.05 Groups: (N=8) Injections P<.05
Slide 26: CDN: Protective Immunity in Preclinical Model
CDN: Protective Immunity in Preclinical Model B16 subcutaneous injection in the flank (Day 0) followed by IV injection (Day 7) ADU-S100 IT treatment course (Days 14, 17, 21) on primary flank tumor Immunity in Lung Metastases Following IT Injection of Primary Tumor * * * Groups: (N=8) B16 Tumor Model
Slide 27: ADU-S100: Solid Tumors or Lymphomas
ADU-S100: Solid Tumors or Lymphomas Two-part study to assess the safety/tolerability in patients with cutaneously accessible, treatment-refractory primary or metastatic solid tumors or lymphomas Part 1: dose escalation in cohorts of 3-6 pts Part 2: dose expansion arms to better characterize safety/e
Slide 28: CDN Breadth of Potential Product and Combination Opportunities
Cyclic Dinucleotides (CDN) Breadth of Potential Product and Combination Opportunities CDN Intratumoral Delivery Oncology Systemic Delivery Oncology Antibody Conjugation Oncology Vaccine Adjuvant Infectious Disease STING Blockade Autoimmunity / Inflammation Vaccine Adjuvant Oncology Not Partnered
Slide 29: Acquisition, Collaborations and Intellectual Property
Acquisition, Collaborations and Intellectual Property
Slide 30: Acquisition of BioNovion in 2015
Acquisition of BioNovion in 2015 Immunotherapy pipeline includes assets that inhibit clinically validated immune checkpoint pathways May be used alone or in combination with the LADD and CDN platforms to increase immunotherapy potency and durability Broad library of therapeutic antibodies APRIL inhi
Slide 31: Robust Collaboration with Janssen Pharmaceuticals
Robust Collaboration with Janssen Pharmaceuticals Initiated two Phase 1 trials in lung and prostate cancer using LADD candidates (ADU-214 and ADU-741) Prostate Cancer Global License to ADU-741 and permitted derivatives $12M upfront $365M total upfront and potential milestones Tiered mid single-digit
Slide 32: Major STING Oncology Collaboration with Novartis
Major STING Oncology Collaboration with Novartis Structure Worldwide covering STING agonists from either company for oncology Joint research and development Aduro leads U.S. commercialization and books U.S. sales NVS leads ex-U.S. commercialization and books ex-U.S. sales Financial Terms $200M upfro
Slide 33: Aduro Maintains Global Rights to Broad Portfolio
Aduro Maintains Global Rights to Broad Portfolio CRS-207 (mesothelin antigen) Pancreatic cancer: Breakthrough Therapy designation with GVAX Pancreas Mesothelioma: Strong Phase 1b response data Additional mesothelin-expressing cancers: i.e. ovarian cancer ADU-623 (NYESO-1 and EGFRvIII antigens) Gliob
Slide 34: Intellectual Property and Exclusivity in the United States
Intellectual Property and Exclusivity in the United States Global Rights (inclusive of in-licensed patents) >200 issued composition and methods patents >50 pending applications Extensive Patent Portfolio and Favorable Regulatory Designations Technology Nominal Expiration Market and Data Exclusivity
Slide 35: Financials and Milestones
Financials and Milestones
Slide 36: 2015 Financials
2015 Financials Cash & cash equivalents as of 9/30/2015 $448.4 M Operating expenses through 9/30/2015 $55.0 M Shares outstanding as of 9/30/2015 62.3 M Strong Financial Position
Slide 37: Significant Catalysts Expected in 2016
Q1 2016 Q2 2016 H1 2016 H2 2016 CRS-207 for Pancreatic Cancer ECLIPSE (GVAX Pancreas + CRS-207) Report Phase 2b top line results STELLAR (nivolumab + GVAX Pancreas + CRS-207) Report Phase 2b interim analysis Finalize Phase 3 trial design CRS-207 for Mesothelioma Report final Phase 1b top line result
Slide 38: Aduro Highlights
Aduro Highlights Three diverse and versatile immunotherapy platforms LADD – novel, live-attenuated Listeria platform to deliver tumor antigens Survival benefit demonstrated in randomized Phase 2 trial in pancreatic cancer trial 94% disease control rate in Phase 1b mesothelioma trial Two Phase 1 tria
Slide 39: Company Overview January 2016
Company Overview January 2016